Key result
Lipid screening, genetic insights, and emerging RNA therapies are essential for individualizing cardiovascular risk prevention.
Why the study?
Lipid testing provides vital information for cardiovascular risk stratification and prevention decision-making.
Lipid profile screening, genetic testing for familial hyperlipidemias, and emerging RNA therapies provide a comprehensive approach to cardiovascular risk stratification and personalized prevention.
Supports lipid screening and genetic evaluation for CV risk; leaves open prospective validation of RNA therapies.
Lipid testing provides vital information for cardiovascular risk stratification and prevention decision-making. This article overviews evidence-based approaches to screening, risk evaluation, diagnosis of familial hyperlipidemias, and employing emerging pharmacogenetic therapies for managing lipid profile abnormalities.
No takes yet. Share an insight, caveat, or question.
Pawan Kumar (2024) conducted a review in Lipid profile abnormalities and familial hyperlipidemias. Lipid profiling and genetic testing was evaluated. Lipid profile screening, recognition of familial hyperlipidemias, and emerging genetic insights and RNA therapies are essential for individualizing cardiovascular risk assessments and prevention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: